PMID- 38318106
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240207
IS  - 0044-5991 (Print)
IS  - 1347-5800 (Electronic)
IS  - 0044-5991 (Linking)
VI  - 56
IP  - 6
DP  - 2023 Dec 28
TI  - Immunohistochemical Analyses of Mammalian Target of Rapamycin (mTOR) Expression 
      in Pituitary Neuroendocrine Tumors (PitNETs): mTOR as a Therapeutic Target for 
      Functional PitNETs.
PG  - 121-126
LID - 10.1267/ahc.23-00039 [doi]
AB  - Current therapeutic modalities for pituitary neuroendocrine tumors (PitNETs) 
      include medication, surgery, and radiotherapy. Some patients have tumors that are 
      refractory to current modalities. Therefore, novel treatment options are needed 
      for patients with intractable diseases. Consequently, we examined the 
      pathological data of PitNETs to study medical therapies. We retrospectively 
      studied 120 patients with histologically diagnosed PitNETs. We used the data for 
      the histopathological examination of hormones, such as growth hormone (GH), 
      prolactin (PRL), adrenocorticotropic hormone, thyroid stimulating hormone, 
      luteinizing hormone, follicle-stimulating hormone, and alpha-subunit, together with 
      the immunohistochemical studies of the phospho-mammalian target of rapamycin 
      (mTOR), cytokeratin (CAM5.2), somatostatin receptor (SSTR) type 2 and 5, Pit-1 
      (POU1F1/GHF-1), steroidogenic factor-1 (SF-1), and Tpit. GH-, PRL-, and 
      SSTR5-immunopositive PitNETs had significantly higher percentage of 
      mTOR-positivity, compared with GH-, PRL-, and SSTR5-immunonegative Pit NETs. Our 
      results show that activation of the AKT/phosphatidylinositol-3-kinase pathway, 
      including mTOR activation, might be related the development of PitNETs, 
      especially GH- and PRL-producing PitNETs. Thus, mTOR is a potential target for 
      treating functional PitNETs.
CI  - 2023 The Japan Society of Histochemistry and Cytochemistry.
FAU - Nakazato, Ichiro
AU  - Nakazato I
AD  - Basic Medical Sciences, International University of Health and Welfare, Graduate 
      School of Medicine, 4-3 Kozunomori, Narita City, Chiba, Japan.
AD  - Department of Neurosurgery, International University of Health and Welfare Mita 
      Hospital, 1-4-3 Mita, Minato-ku, Tokyo, Japan.
FAU - Shiomi, Takayuki
AU  - Shiomi T
AD  - Department of Pathology, International University of Health and Welfare Narita 
      Hospital, 852 Hatakeda, Narita City, Chiba, Japan.
FAU - Oyama, Kenichi
AU  - Oyama K
AD  - Department of Neurosurgery, International University of Health and Welfare Mita 
      Hospital, 1-4-3 Mita, Minato-ku, Tokyo, Japan.
FAU - Matsuno, Akira
AU  - Matsuno A
AD  - Department of Neurosurgery, International University of Health and Welfare Mita 
      Hospital, 1-4-3 Mita, Minato-ku, Tokyo, Japan.
AD  - Department of Neurosurgery, International University of Health and Welfare Narita 
      Hospital, 852 Hatakeda, Narita City, Chiba, Japan.
FAU - Inomoto, Chie
AU  - Inomoto C
AD  - Department of Diagnostic Pathology, Tokai University Hospital, 143 Shimokasuya, 
      Isehara City, Kanagawa, Japan.
FAU - Yoshiyuki Osamura, R
AU  - Yoshiyuki Osamura R
AD  - Department of Diagnostic Pathology, Nippon Koukan Hospital, 1-2-1, Koukan-Dori, 
      Kawasaki-ku, Kawasaki City, Kanagawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231220
PL  - Japan
TA  - Acta Histochem Cytochem
JT  - Acta histochemica et cytochemica
JID - 0147110
PMC - PMC10838633
OTO - NOTNLM
OT  - immunohistochemistry
OT  - phospho-mammalian target of rapamycin (mTOR)
OT  - pituitary neuroendocrine tumor
COIS- VThe authors declare that there are no conflicts of interest.
EDAT- 2024/02/06 06:42
MHDA- 2024/02/06 06:43
PMCR- 2023/12/28
CRDT- 2024/02/06 03:51
PHST- 2023/05/26 00:00 [received]
PHST- 2023/10/13 00:00 [accepted]
PHST- 2024/02/06 06:43 [medline]
PHST- 2024/02/06 06:42 [pubmed]
PHST- 2024/02/06 03:51 [entrez]
PHST- 2023/12/28 00:00 [pmc-release]
AID - JST.JSTAGE/ahc/23-00039 [pii]
AID - 10.1267/ahc.23-00039 [doi]
PST - ppublish
SO  - Acta Histochem Cytochem. 2023 Dec 28;56(6):121-126. doi: 10.1267/ahc.23-00039. 
      Epub 2023 Dec 20.